TRex Bio utilizes a human tissue-based Deep Biology Platform to map Treg behavior and identify novel therapeutics for immune-mediated diseases. By leveraging advanced sequencing and computational tools, the company aims to restore tissue homeostasis and mitigate inflammation in conditions such as cancer and fibrosis.
Funding
$84M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many immune-mediated diseases lack effective treatments because drug discovery often fails to fully account for the complexities of human tissue biology and the behavior of regulatory T cells (Tregs) within those tissues. Current approaches may not accurately identify and target the specific mechanisms driving inflammation and tissue damage in these diseases.
Solution
TRex Bio employs a Deep Biology Platform that analyzes human tissue samples to map Treg behavior and identify novel therapeutic targets for immune-mediated diseases. By combining advanced sequencing, computational tools, and disease-relevant human assay systems, the platform generates insights into the dysregulation of Tregs in diseased tissues. This approach enables the development of therapeutics designed to restore tissue homeostasis and resolve inflammation by modulating Treg activity at the site of disease.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies focused on developing novel therapies for immune-mediated diseases, as well as researchers studying Treg biology and tissue inflammation.
Features
- Human tissue-based Deep Biology Platform for mapping Treg behavior in healthy and diseased tissues
- Advanced sequencing technologies to analyze tissue samples at high resolution
- Computational tools and machine learning algorithms to identify key pathways and therapeutic targets
- Disease-relevant human assay systems to validate drug candidates
- Focus on developing therapeutics that modulate Treg activity to restore tissue homeostasis